KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of “Moderate Buy” from Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $29.40.

Several equities research analysts have recently issued reports on KALV shares. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Needham & Company LLC raised their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Citizens Jmp dropped their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, HC Wainwright boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 10,034 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $156,229.38. Following the completion of the sale, the chief executive officer owned 442,883 shares of the company’s stock, valued at approximately $6,895,688.31. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Nicole Sweeny sold 3,975 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the sale, the insider owned 47,003 shares of the company’s stock, valued at $731,836.71. This represents a 7.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 33,979 shares of company stock valued at $535,091. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of KALV. BNP Paribas Financial Markets lifted its position in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals in the third quarter worth $55,000. Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at $57,000. KLP Kapitalforvaltning AS purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at $63,000. Finally, Truvestments Capital LLC lifted its holdings in shares of KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,360 shares in the last quarter.

KalVista Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ KALV opened at $16.23 on Friday. The firm’s 50-day moving average is $15.57 and its two-hundred day moving average is $14.11. The company has a market capitalization of $820.43 million, a PE ratio of -4.11 and a beta of -0.35. KalVista Pharmaceuticals has a 12-month low of $9.23 and a 12-month high of $19.00. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.